214147-48-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-AMINO-PIPERIDIN-1-YL)-ETHANONE HCL is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Chemical Industry:
1-(4-AMINO-PIPERIDIN-1-YL)-ETHANONE HCL is used as a building block in the synthesis of organic compounds, facilitating the creation of a range of chemical products that can be utilized in different sectors, including but not limited to, materials science, agrochemicals, and specialty chemicals.
The specific applications and industries where 1-(4-AMINO-PIPERIDIN-1-YL)-ETHANONE HCL is utilized may vary, but its role as an intermediate in synthesis processes is a common thread across these uses, highlighting its importance in the development of new chemical entities and pharmaceuticals.

Upstream product

• 283167-28-2 tert-butyl (1-acetylpiperidin-4-yl)carbamate 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 

Downstream Products

• 283167-10-2 1-(1-acetyl-piperidin-4-yl)-3-(4-fluoro-phenyl)-urea 
• 283167-05-5 1-acetyl-4-(4-fluorophenoxycarbonylamino)piperidine 
• 1884246-71-2 6-((1-acetylpiperidin-4-yl)amino)pyrimidine-4-carboxylic acid 
• 283167-06-6 N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide 

Relevant academic research and scientific papers

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula (I) wherein: R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS

The invention relates to a compound of formula (I) or a salt thereof: wherein:R1 is C1-4alkyl, C1-3fluoroalkyl, -CH2CH2OH or -CH2CH2CO2C1-2alkyl;R2 is a hydrogen atom (H), methyl or C1fluoroalkyl;R3 is optionally substituted C3-8cycloalkyl or optionally substituted mono-unsaturated-C5-7cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n1 and n2 independently are 1 or 2; and in which Y is O, S, SO2, or NR10; or R3 is a bicyclic group (dd) or (ee): ; and wherein X is NR4R5 or OR5a. The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.